免疫检查点抑制剂相关自身免疫性溶血性贫血的临床与实验室特征
美国九家机构共14例免疫检查点抑制剂相关自身免疫性溶血性贫血(ICPi-AIHA)患者,中位发病间隔55天,直接抗人球蛋白试验(DAT)阳性8例(62%)、阴性5例(38%),所有患者接受糖皮质激素治疗,完全缓解12例(86%)、部分缓解2例(14%),7例(50%)再次接受ICPi治疗,其中1例(14%)复发。
要点
- ICPi-AIHA中位发病间隔55天,DAT阴性比例较高(5/13,38%)。
- 所有患者接受糖皮质激素治疗,完全缓解12例(86%)、部分缓解2例(14%)。
- 7例(50%)再次接受ICPi治疗,仅1例(14%)复发AIHA。
核心结论
- ICPi-AIHA与原发性AIHA临床特征相似,但DAT阴性发生率高;糖皮质激素是多数患者有效的一线治疗,再次接受ICPi治疗者多数未见AIHA复发。
研究设计与样本
- 从美国九家机构识别14例发生ICPi-AIHA的患者进行临床与实验室特征分析。
主要发现
- 从ICPi启动至AIHA发生的中位间隔为55天(四分位距[IQR],22-110天)。
- 14例中13例有DAT结果:DAT阳性8例(62%),DAT阴性5例(38%)。
- 治疗前中位血红蛋白为11.8 g/dL(IQR,10.2-12.9 g/dL),最低中位血红蛋白为6.3 g/dL(IQR,6.1-8.0 g/dL)。
- 4例(29%)有既存淋巴增殖性疾病,2例(14%)在ICPi治疗前DAT阳性。
- 所有患者接受糖皮质激素治疗,其中3例需额外免疫抑制治疗;血红蛋白完全恢复12例(86%)、部分恢复2例(14%)。
关键数值与推荐
- DAT阳性与阴性ICPi-AIHA患者的临床和实验室特征相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi-AIHA. The median interval from ICPi initiation to development of AIHA was 55 days (interquartile range [IQR], 22-110 days). Results from the direct antiglobulin test (DAT) were available for 13 of 14 patients: 8 patients (62%) had a positive DAT and 5 (38%) had a negative DAT. The median pretreatment and nadir hemoglobin concentrations were 11.8 g/dL (IQR, 10.2-12.9 g/dL) and 6.3 g/dL (IQR, 6.1-8.0 g/dL), respectively. Four patients (29%) had a preexisting lymphoproliferative disorder, and two (14%) had a positive DAT prior to initiation of ICPi therapy. All patients were treated with glucocorticoids, with three requiring additional immunosuppressive therapy. Complete and partial recoveries of hemoglobin were achieved in 12 (86%) and 2 (14%) patients, respectively. Seven patients (50%) were rechallenged with ICPis, and one (14%) developed recurrent AIHA. Clinical and laboratory features of ICPi-AIHA were similar in DAT positive and negative patients. ICPi-AIHA shares many clinical features with primary AIHA; however, a unique aspect of ICPi-AIHA is a high incidence of DAT negativity. Glucocorticoids are an effective first-line treatment in the majority of patients with ICPi-AIHA, and most patients who are rechallenged with an ICPi do not appear to develop recurrence of AIHA.
引用
- Leaf RK, Ferreri C, Rangachari D, et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019. PMID: 30790338. doi:10.1002/ajh.25448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。